(a) As used in this section and Section 83-9-605, the following terms shall be defined as provided in this section:(a) “Biomarker” means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a specific therapeutic intervention, including known gene-drug interactions for medications being considered for use or already being administered. Biomarkers include, but are not limited to, gene mutations, characteristics of genes, or protein expression.(b) “Biomarker testing” means the analysis of a patient’s tissue, blood or other biospecimen for the presence of a biomarker. Biomarker testing includes, but is not limited to, single-analyte tests, multi-plex panel tests, protein expression, whole exome, whole genome, and whole transcriptome sequencing and other genomic or molecular sequencing.(c) “Consensus statement” means a statement developed by an independent, multidisciplinary panel of experts using a transparent methodology and reporting structure and with a conflict of interest policy. A consensus statement is aimed at specific clinical circumstances and the statement is based on the best available evidence for the purpose of optimizing the outcomes of clinical care.(d) “Health benefit plan” has the meaning given to that term in Section 83-9-6.3, and also includes nonprofit health service plans and the State and School Employees Health Insurance Plan.(e) “Health insurance issuer” has the meaning given to that term in Section 83-9-6.3.(f) “Nationally recognized clinical practice guidelines” means evidence-based clinical practice guidelines developed by independent organizations or medical professional societies using a transparent methodology and reporting structure and with a conflict of interest policy. Clinical practice guidelines establish standards of care informed by a systematic review of evidence and an assessment of the benefits and risks of alternative care options and include recommendations intended to optimize patient care.
(a) “Biomarker” means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a specific therapeutic intervention, including known gene-drug interactions for medications being considered for use or already being administered. Biomarkers include, but are not limited to, gene mutations, characteristics of genes, or protein expression.
(b) “Biomarker testing” means the analysis of a patient’s tissue, blood or other biospecimen for the presence of a biomarker. Biomarker testing includes, but is not limited to, single-analyte tests, multi-plex panel tests, protein expression, whole exome, whole genome, and whole transcriptome sequencing and other genomic or molecular sequencing.
(c) “Consensus statement” means a statement developed by an independent, multidisciplinary panel of experts using a transparent methodology and reporting structure and with a conflict of interest policy. A consensus statement is aimed at specific clinical circumstances and the statement is based on the best available evidence for the purpose of optimizing the outcomes of clinical care.
(d) “Health benefit plan” has the meaning given to that term in Section 83-9-6.3, and also includes nonprofit health service plans and the State and School Employees Health Insurance Plan.
(e) “Health insurance issuer” has the meaning given to that term in Section 83-9-6.3.
(f) “Nationally recognized clinical practice guidelines” means evidence-based clinical practice guidelines developed by independent organizations or medical professional societies using a transparent methodology and reporting structure and with a conflict of interest policy. Clinical practice guidelines establish standards of care informed by a systematic review of evidence and an assessment of the benefits and risks of alternative care options and include recommendations intended to optimize patient care.